Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Advanced MYCHELANGELO™ I trial dose escalation to Cohort 5; Presentation of additional monotherapy data and planned expansion into Phase 2 settings expected in mid-2024Presented new preclinical data.
CAMBRIDGE, Mass., April 23, 2024 Omega Therapeutics, Inc. , a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today.
GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave’s next generation.
Moonwalk Biosciences to Present Data Showcasing EpiRead™ and EpiWrite™ Next-Generation Multiplex Epigenetic Engineering Platform at ASGCT 2024 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.